A Phase 2 interventional study of LY3437943 and Dulaglutide in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 43 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-07-03.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing retatrutide in Diabetes Mellitus, Type 2 — none open to participants now, 3 under way, 3 of them phase 3. retatrutide · Diabetes Mellitus, Type 2.
Among the 10 studies testing retatrutide in Diabetes Mellitus, Type 2, this one is the 6th largest by enrollment, is one of 2 that started in 2021, is one of 2 in phase 2, and was the 3rd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 10 studies testing retatrutide in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 2 started in 2021.
This study's enrollment of 281 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 301 across the 10 interventional studies. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 1 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 101st largest by enrollment of the 232 interventional ones that give a count, is one of 9 that started in 2021, is one of 34 in phase 2, and was the 175th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing retatrutide in Diabetes Mellitus, Type 2, from their registry updates:
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the efficacy and safety of LY3437943 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin. This study will last about 43 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 0.5 mg LY3437943 administered as SC (subcutaneous) injection once weekly (QW).
Drug: LY3437943
Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.
Drug: LY3437943
Participants received 4 mg LY3437943 administered as SC injection QW.
Drug: LY3437943
Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.
Drug: LY3437943
Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as a SC injection QW.
Drug: LY3437943
Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, then 8 mg LY3437943, then 12 mg LY3437943 administered as a SC injection QW.
Drug: LY3437943
Participants received 1.5 mg dulaglutide administered as SC single-dose pen injection QW.
Drug: Dulaglutide
Participants received placebo administered as SC injection QW.
Drug: Placebo
Administered SC
Administered SC
Administered SC
Change From Baseline in Hemoglobin A1c (HbA1c)
Change in HbA1c (%) from baseline in LY3437943 relative to placebo. HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least squares (LS) mean was calculated using mixed model repeated measures (MMRM) for post-baseline measures: Variable = Treatment\*Time + Strata\*Time + Baseline\*Time.
Time frame: Baseline, 24 Weeks
Change From Baseline in HbA1c
Change in HbA1c (%) from baseline in LY3437943 relative to dulaglutide. LSMean was calculated using MMRM for post-baseline measures: Variable = Treatment\*Time + Strata\*Time + Baseline\*Time.
Time frame: Baseline, 24 Weeks
Change From Baseline in HbA1c
Change in HbA1c (%) from baseline in LY3437943 relative to placebo and dulaglutide. LSMean was calculated using MMRM for post-baseline measures: Variable = Treatment\*Time + Baseline HbA1c Group (\<=8.5%, \>8.5%)\*Time + Baseline Body Mass Index (BMI) Group (\<30 kilograms/square meter (kg/m2), \>=30 kg/m2)\*Time + Baseline\*Time.
Time frame: Baseline, 36 Weeks
Percentage of Participants Reaching HbA1c <7.0%
Percentage of participants reaching HbA1c \<7.0% in LY3437943 relative to placebo and dulaglutide. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<30 kg/m2, ≥30 kg/m2\] as fixed effects, and baseline HbA1c value as a covariate.
Time frame: Week 24
Percentage of Participant Reaching HbA1c <7.0%
Percentage of participants reaching HbA1c \<7.0% in LY3437943 relative to placebo and dulaglutide. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<30 kg/m2, ≥30 kg/m2\] as fixed effects, and baseline HbA1c value as a covariate.
Time frame: Week 36
Change From Baseline in Fasting Blood Glucose (FBG)
Change in FBG from baseline in LY3437943 relative to placebo and dulaglutide. LSMean was calculated using MMRM for post-baseline measures: Variable = Treatment\*Time + Strata\*Time + Baseline\*Time.
Time frame: Baseline, 24 Weeks
Change From Baseline in Fasting Blood Glucose (FBG)
Change in FBG from baseline in LY3437943 relative to placebo and dulaglutide. LSMean was calculated using MMRM for post-baseline measures: Variable = Treatment\*Time + Baseline HbA1c Group (\<=8.5%, \>8.5%)\*Time + Baseline BMI Group (\<30kg/m2, \>=30kg/m2)\*Time + Baseline\*Time.
Time frame: Baseline, 36 Weeks
Change From Baseline in Body Weight
Change in body weight from baseline in LY3437943 relative to placebo and dulaglutide. LSMean was calculated using MMRM for post-baseline measures: Variable = Treatment\*Time + Strata\*Time + Baseline\*Time.
Time frame: Baseline, 24 Weeks
Change From Baseline in Body Weight
Change in body weight from baseline in LY3437943 relative to placebo and dulaglutide. LSMean was calculated using MMRM for post-baseline measures: Variable = Treatment\*Time + Baseline HbA1c Group (\<=8.5%, \>8.5%)\*Time + Baseline BMI Group (\<30kg/m2, \>=30kg/m2)\*Time + Baseline\*Time.
Time frame: Baseline, 36 Weeks
Population PK: Average Steady-State Plasma Concentration (Cav,ss) of LY3437943
The average steady-state plasma concentration of LY3437943 was evaluated using sparse sampling methodology/Population PK (PopPK) modeling.
Time frame: Predose: Week 0, 1, 4, 12, 24, 30; Postdose: Week 2, 8, 16, 20, 36
| Milestone | Placebo | 1.5 Milligrams (mg) Dulaglutide | 0.5 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 (4 mg) | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) |
|---|---|---|---|---|---|---|---|---|
| Started | 45 | 46 | 47 | 23 | 24 | 26 | 24 | 46 |
| Received at least 1 dose of study drug | 45 | 46 | 47 | 23 | 24 | 26 | 24 | 46 |
| Completed | 34 | 40 | 41 | 19 | 21 | 25 | 22 | 35 |
| Not completed | 11 | 6 | 6 | 4 | 3 | 1 | 2 | 11 |
| Withdrew: Adverse event | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 4 | 4 | 3 | 2 | 0 | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 6 | 2 | 2 | 1 | 2 | 0 | 2 | 5 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Inadvertent enrollment | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 |
| Withdrew: Eligibility criteria not met | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Change in HbA1c (%) from baseline in LY3437943 relative to placebo. HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least squares (LS) mean was calculated using mixed model repeated measures (MMRM) for post-baseline measures: Variable = Treatment\*Time + Strata\*Time + Baseline\*Time.
| percentage of HbA1c | Placebo | 1.5 mg Dulaglutide | 0.5 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 (4 mg) | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) | -0.05 ± 0.21 | -1.41 ± 0.12 | -0.43 ± 0.20 | -1.39 ± 0.14 | -1.30 ± 0.22 | -1.99 ± 0.15 | -1.88 ± 0.21 | -2.01 ± 0.11 |
Change in HbA1c (%) from baseline in LY3437943 relative to dulaglutide. LSMean was calculated using MMRM for post-baseline measures: Variable = Treatment\*Time + Strata\*Time + Baseline\*Time.
| percentage of HbA1c | Placebo | 1.5 Milligram (mg) Dulaglutide | 0.5 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 (4 mg) | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in HbA1c | -0.05 ± 0.21 | -1.41 ± 0.12 | -0.43 ± 0.20 | -1.39 ± 0.14 | -1.30 ± 0.22 | -1.99 ± 0.15 | -1.88 ± 0.21 | -2.01 ± 0.11 |
Change in HbA1c (%) from baseline in LY3437943 relative to placebo and dulaglutide. LSMean was calculated using MMRM for post-baseline measures: Variable = Treatment\*Time + Baseline HbA1c Group (\<=8.5%, \>8.5%)\*Time + Baseline Body Mass Index (BMI) Group (\<30 kilograms/square meter (kg/m2), \>=30 kg/m2)\*Time + Baseline\*Time.
| percentage of HbA1c | Placebo | 1.5 Milligram (mg) Dulaglutide | 0.5 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 (4 mg) | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in HbA1c | -0.30 ± 0.24 | -1.36 ± 0.13 | -0.54 ± 0.20 | -1.30 ± 0.20 | -1.50 ± 0.19 | -2.13 ± 0.17 | -1.93 ± 0.22 | -2.16 ± 0.13 |
Percentage of participants reaching HbA1c \<7.0% in LY3437943 relative to placebo and dulaglutide. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<30 kg/m2, ≥30 kg/m2\] as fixed effects, and baseline HbA1c value as a covariate.
| percentage of participants | Placebo | 1.5 Milligram (mg) Dulaglutide | 0.5 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 (4 mg) | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Reaching HbA1c <7.0% | 18 | 52 | 32 | 53 | 66 | 88 | 78 | 86 |
Percentage of participants reaching HbA1c \<7.0% in LY3437943 relative to placebo and dulaglutide. Estimated percentage was determined by logistic regression model with an intercept term, treatment group, baseline BMI stratum \[\<30 kg/m2, ≥30 kg/m2\] as fixed effects, and baseline HbA1c value as a covariate.
| percentage of participants | Placebo | 1.5 Milligram (mg) Dulaglutide | 0.5 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 (4 mg) | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participant Reaching HbA1c <7.0% | 22 | 60 | 37 | 61 | 59 | 82 | 78 | 80 |
Change in FBG from baseline in LY3437943 relative to placebo and dulaglutide. LSMean was calculated using MMRM for post-baseline measures: Variable = Treatment\*Time + Strata\*Time + Baseline\*Time.
| milligrams/deciliter (mg/dL) | Placebo | 1.5 Milligram (mg) Dulaglutide | 0.5 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 (4 mg) | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Fasting Blood Glucose (FBG) | -10.59 ± 5.98 | -46.26 ± 4.35 | -12.71 ± 6.95 | -30.19 ± 12.65 | -43.89 ± 8.42 | -66.09 ± 3.70 | -39.80 ± 10.79 | -65.20 ± 4.38 |
Change in FBG from baseline in LY3437943 relative to placebo and dulaglutide. LSMean was calculated using MMRM for post-baseline measures: Variable = Treatment\*Time + Baseline HbA1c Group (\<=8.5%, \>8.5%)\*Time + Baseline BMI Group (\<30kg/m2, \>=30kg/m2)\*Time + Baseline\*Time.
| mg/dL | Placebo | 1.5 Milligram (mg) Dulaglutide | 0.5 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 (4 mg) | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Fasting Blood Glucose (FBG) | -17.26 ± 10.87 | -27.53 ± 9.07 | -17.51 ± 5.59 | -21.46 ± 12.54 | -38.72 ± 10.81 | -69.10 ± 4.68 | -41.20 ± 14.43 | -67.84 ± 4.79 |
Change in body weight from baseline in LY3437943 relative to placebo and dulaglutide. LSMean was calculated using MMRM for post-baseline measures: Variable = Treatment\*Time + Strata\*Time + Baseline\*Time.
| kilograms (kg) | Placebo | 1.5 Milligram (mg) Dulaglutide | 0.5 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 (4 mg) | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Body Weight | -1.86 ± 0.66 | -1.16 ± 0.63 | -2.35 ± 0.48 | -6.27 ± 0.94 | -8.64 ± 1.23 | -11.99 ± 0.84 | -13.91 ± 1.38 | -12.84 ± 0.93 |
Change in body weight from baseline in LY3437943 relative to placebo and dulaglutide. LSMean was calculated using MMRM for post-baseline measures: Variable = Treatment\*Time + Baseline HbA1c Group (\<=8.5%, \>8.5%)\*Time + Baseline BMI Group (\<30kg/m2, \>=30kg/m2)\*Time + Baseline\*Time.
| kilograms (kg) | Placebo | 1.5 Milligram (mg) Dulaglutide | 0.5 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 (4 mg) | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Body Weight | -3.28 ± 0.92 | -1.97 ± 0.87 | -3.31 ± 0.62 | -7.28 ± 1.39 | -10.37 ± 1.49 | -16.48 ± 1.55 | -16.12 ± 1.63 | -17.18 ± 1.32 |
The average steady-state plasma concentration of LY3437943 was evaluated using sparse sampling methodology/Population PK (PopPK) modeling.
| nanograms/milliliter (ng/mL) | 0.5 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 (4 mg) | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) |
|---|---|---|---|---|---|---|
| Population PK: Average Steady-State Plasma Concentration (Cav,ss) of LY3437943 | 62.8 | 466 | 551 | 1100 | 1140 | 1620 |
Collected over Baseline Through Study Completion (Up to 280 Days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/45 (0%) | 3/45 (6.7%) | 15/45 (33.3%) |
| 1.5 Milligram (mg) Dulaglutide | 0/46 (0%) | 1/46 (2.2%) | 24/46 (52.2%) |
| 0.5 mg LY3437943 | 0/47 (0%) | 3/47 (6.4%) | 15/47 (31.9%) |
| 4 mg LY3437943 (2 mg) | 0/23 (0%) | 1/23 (4.3%) | 9/23 (39.1%) |
| 4 mg LY3437943 (4 mg) | 0/24 (0%) | 2/24 (8.3%) | 17/24 (70.8%) |
| 8 mg LY3437943 (2 mg) | 0/26 (0%) | 2/26 (7.7%) | 16/26 (61.5%) |
| 8 mg LY3437943 (4 mg) | 0/24 (0%) | 1/24 (4.2%) | 15/24 (62.5%) |
| 12 mg LY3437943 (2 mg) | 0/46 (0%) | 2/46 (4.3%) | 25/46 (54.3%) |
| Event | Placebo | 1.5 Milligram (mg) Dulaglutide | 0.5 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 (4 mg) | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) |
|---|---|---|---|---|---|---|---|---|
| Transurethral prostatectomySurgical and medical procedures | 1/22 | 0/13 | 0/24 | 0/15 | 0/12 | 0/10 | 0/9 | 0/20 |
| Cardiac failure congestiveCardiac disorders | 0/45 | 0/46 | 1/47 | 1/23 | 0/24 | 0/26 | 0/24 | 0/46 |
| Cholecystitis chronicHepatobiliary disorders | 0/45 | 0/46 | 0/47 | 0/23 | 0/24 | 0/26 | 1/24 | 0/46 |
| Osteomyelitis acuteInfections and infestations | 0/45 | 0/46 | 0/47 | 0/23 | 1/24 | 0/26 | 0/24 | 0/46 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/45 | 0/46 | 0/47 | 0/23 | 1/24 | 0/26 | 0/24 | 0/46 |
| Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/45 | 0/46 | 0/47 | 0/23 | 1/24 | 0/26 | 0/24 | 0/46 |
| Atrial fibrillationCardiac disorders | 0/45 | 0/46 | 0/47 | 0/23 | 0/24 | 1/26 | 0/24 | 0/46 |
| Pancreatitis acuteGastrointestinal disorders | 0/45 | 0/46 | 1/47 | 0/23 | 0/24 | 1/26 | 0/24 | 0/46 |
| Abdominal herniaGastrointestinal disorders | 1/45 | 0/46 | 0/47 | 0/23 | 0/24 | 0/26 | 0/24 | 0/46 |
| CellulitisInfections and infestations | 1/45 | 0/46 | 0/47 | 0/23 | 0/24 | 0/26 | 0/24 | 1/46 |
| Event | Placebo | 1.5 Milligram (mg) Dulaglutide | 0.5 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 (4 mg) | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) |
|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 2/45 | 8/46 | 2/47 | 2/23 | 6/24 | 7/26 | 10/24 | 9/46 |
| DiarrhoeaGastrointestinal disorders | 2/45 | 4/46 | 1/47 | 2/23 | 6/24 | 5/26 | 7/24 | 7/46 |
| Decreased appetiteMetabolism and nutrition disorders | 0/45 | 6/46 | 2/47 | 1/23 | 5/24 | 5/26 | 4/24 | 9/46 |
| ConstipationGastrointestinal disorders | 1/45 | 3/46 | 3/47 | 2/23 | 4/24 | 3/26 | 2/24 | 5/46 |
| VomitingGastrointestinal disorders | 1/45 | 4/46 | 1/47 | 1/23 | 0/24 | 2/26 | 4/24 | 5/46 |
| Covid-19Infections and infestations | 3/45 | 4/46 | 5/47 | 3/23 | 1/24 | 1/26 | 1/24 | 2/46 |
| FlatulenceGastrointestinal disorders | 0/45 | 1/46 | 0/47 | 0/23 | 1/24 | 0/26 | 3/24 | 0/46 |
| FatigueGeneral disorders | 0/45 | 0/46 | 1/47 | 1/23 | 2/24 | 1/26 | 3/24 | 3/46 |
| Urinary tract infectionInfections and infestations | 2/45 | 1/46 | 0/47 | 0/23 | 1/24 | 1/26 | 3/24 | 5/46 |
| DizzinessNervous system disorders | 1/45 | 1/46 | 0/47 | 2/23 | 2/24 | 1/26 | 3/24 | 2/46 |
All randomized participants
| Age, Continuous(years) | Placebo | 1.5 mg Dulaglutide | 0.5 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 (4 mg) | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 57.56 ± 10.83 | 54.94 ± 10.45 | 57.21 ± 9.69 | 57.70 ± 8.14 | 57.58 ± 10.00 | 57.00 ± 7.37 | 53.83 ± 9.03 | 54.37 ± 9.72 | 56.19 ± 9.68 |
| Sex: Female, Male(Participants) | Placebo | 1.5 mg Dulaglutide | 0.5 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 (4 mg) | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 23 | 33 | 23 | 8 | 12 | 16 | 15 | 26 | 156 |
| Male | 22 | 13 | 24 | 15 | 12 | 10 | 9 | 20 | 125 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 1.5 mg Dulaglutide | 0.5 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 (4 mg) | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 21 | 20 | 27 | 9 | 13 | 12 | 9 | 20 | 131 |
| Not Hispanic or Latino | 23 | 26 | 20 | 14 | 10 | 14 | 15 | 26 | 148 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Placebo | 1.5 mg Dulaglutide | 0.5 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 (4 mg) | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Asian | 3 | 1 | 0 | 2 | 0 | 0 | 0 | 2 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 5 | 9 | 6 | 1 | 2 | 3 | 4 | 3 | 33 |
| White | 36 | 36 | 40 | 20 | 22 | 23 | 20 | 38 | 235 |
| More than one race | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Region of Enrollment(participants) | Placebo | 1.5 mg Dulaglutide | 0.5 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 (4 mg) | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) | Total |
|---|---|---|---|---|---|---|---|---|---|
| United States | 45 | 46 | 47 | 23 | 24 | 26 | 24 | 46 | 281 |
| Percentage of Hemoglobin A1c (HbA1c) at Baseline(Percentage of HbA1c) | Placebo | 1.5 mg Dulaglutide | 0.5 mg LY3437943 | 4 mg LY3437943 (2 mg) | 4 mg LY3437943 (4 mg) | 8 mg LY3437943 (2 mg) | 8 mg LY3437943 (4 mg) | 12 mg LY3437943 (2 mg) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 8.39 ± 1.139 | 8.22 ± 0.919 | 8.35 ± 1.172 | 8.07 ± 0.870 | 8.20 ± 1.207 | 8.34 ± 1.120 | 8.20 ± 1.261 | 8.28 ± 1.066 | 8.27 ± 1.086 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from May 2021 to primary completion in Jul 2022, 13 months.
Results were first posted in Jul 2023, 11 months after primary completion.
Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 13 months is close to that.
Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Retatrutide